Crescent Grove Advisors’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.79M | Sell |
28,392
-6
| -0% | -$1.03K | 0.46% | 51 |
|
|
2025
Q4 | $4.79M | Sell |
28,398
-2,147
| -7% | -$349K | 0.44% | 51 |
|
|
2025
Q3 | $4.41M | Sell |
30,545
-1,127
| -4% | -$154K | 0.42% | 55 |
|
|
2025
Q2 | $4.01M | Sell |
31,672
-730
| -2% | -$89.6K | 0.39% | 56 |
|
|
2025
Q1 | $4.14M | Sell |
32,402
-1,944
| -6% | -$264K | 0.43% | 49 |
|
|
2024
Q4 | $4.54M | Sell |
34,346
-8,454
| -20% | -$1.19M | 0.45% | 48 |
|
|
2024
Q3 | $6.23M | Sell |
42,800
-749
| -2% | -$108K | 0.64% | 30 |
|
|
2024
Q2 | $5.98M | Sell |
43,549
-4,161
| -9% | -$555K | 0.65% | 31 |
|
|
2024
Q1 | $6.55M | Sell |
47,710
-4,528
| -9% | -$618K | 0.68% | 31 |
|
|
2023
Q4 | $7.1M | Sell |
52,238
-5,683
| -10% | -$693K | 0.79% | 27 |
|
|
2023
Q3 | $7.09M | Sell |
57,921
-11,804
| -17% | -$1.5M | 0.88% | 23 |
|
|
2023
Q2 | $8.85M | Sell |
69,725
-2,878
| -4% | -$374K | 0.95% | 23 |
|
|
2023
Q1 | $9.38M | Sell |
72,603
-4,391
| -6% | -$575K | 1.09% | 23 |
|
|
2022
Q4 | $10.1M | Buy |
76,994
+3,765
| +5% | +$487K | 1.05% | 24 |
|
|
2022
Q3 | $8.56M | Buy |
73,229
+439
| +0.6% | +$54.5K | 0.99% | 22 |
|
|
2022
Q2 | $8.56M | Buy |
72,790
+12,032
| +20% | +$1.43M | 0.9% | 23 |
|
|
2022
Q1 | $7.92M | Buy |
60,758
+7,128
| +13% | +$928K | 0.78% | 23 |
|
|
2021
Q4 | $8.19M | Buy |
53,630
+8,272
| +18% | +$1.28M | 0.77% | 23 |
|
|
2021
Q3 | $7.33M | Buy |
45,358
+1,605
| +4% | +$270K | 0.78% | 22 |
|
|
2021
Q2 | $7.16M | Buy |
43,753
+1,308
| +3% | +$201K | 0.75% | 24 |
|
|
2021
Q1 | $6.39M | Sell |
42,445
-3,238
| -7% | -$514K | 0.75% | 27 |
|
|
2020
Q4 | $6.92M | Buy |
45,683
+2,797
| +7% | +$400K | 0.9% | 25 |
|
|
2020
Q3 | $5.81M | Buy |
42,886
+1,545
| +4% | +$210K | 1.16% | 20 |
|
|
2020
Q2 | $5.65M | Sell |
41,341
-545
| -1% | -$69.5K | 1.19% | 18 |
|
|
2020
Q1 | $4.51M | Sell |
41,886
-2,601
| -6% | -$299K | 1% | 22 |
|
|
2019
Q4 | $5.36M | Sell |
44,487
-521
| -1% | -$58.1K | 0.93% | 23 |
|
|
2019
Q3 | $4.48M | Buy |
45,008
+14
| +0% | +$1.47K | 0.86% | 25 |
|
|
2019
Q2 | $4.91M | Sell |
44,994
-2,674
| -6% | -$284K | 0.93% | 21 |
|
|
2019
Q1 | $5.33M | Sell |
47,668
-12,239
| -20% | -$1.34M | 1.09% | 18 |
|
|
2018
Q4 | $5.78M | Sell |
59,907
-14,267
| -19% | -$1.51M | 1.23% | 19 |
|
|
2018
Q3 | $9.05M | Sell |
74,174
-85
| -0.1% | -$10K | 1.95% | 10 |
|
|
2018
Q2 | $8.17M | Sell |
74,259
-6,323
| -8% | -$676K | 2.03% | 10 |
|
|
2018
Q1 | $8.6M | Buy |
80,582
+6,476
| +9% | +$718K | 2.11% | 9 |
|
|
2017
Q4 | $7.91M | Buy |
74,106
+13,311
| +22% | +$1.42M | 1.99% | 9 |
|
|
2017
Q3 | $6.76M | Buy |
60,795
+5,844
| +11% | +$625K | 1.73% | 10 |
|
|
2017
Q2 | $5.68M | Buy |
+54,951
| New | +$5.41M | 1.64% | 13 |
|
Other funds holding IBB
CB
Crescent Grove Advisors's IBB Position: Q1 2026 in Review
Crescent Grove Advisors reduced its iShares Biotechnology ETF (IBB) stake by 0.02% in Q1 2026, selling an estimated $1.03K and leaving 28,392 shares worth $4.79M. The position accounts for 0.46% of the portfolio, ranked #51.
Crescent Grove Advisors first reported a position in IBB in Q2 2017 and has held it in 36 quarters since. The position peaked at $10.1M in Q4 2022. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.
- Crescent Grove Advisors held 28,392 shares of iShares Biotechnology ETF worth $4.79M as of Q1 2026.
- Crescent Grove Advisors sold 6 iShares Biotechnology ETF shares in Q1 2026, an estimated $1.03K.
- iShares Biotechnology ETF made up 0.46% of Crescent Grove Advisors's portfolio in Q1 2026, its #51 holding.
- Crescent Grove Advisors first reported a position in iShares Biotechnology ETF in Q2 2017 and has held it in 36 quarters since.
- Crescent Grove Advisors's iShares Biotechnology ETF position peaked at $10.1M in Q4 2022.
- 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.
Based on Crescent Grove Advisors's 13F filing for Q1 2026, filed 6 May 2026.